NFKB1 and ischemic stroke: In conclusion, the current findings indicate that CSO treatment can alleviate ischemic stroke injury via reducing inflammatory microglia and astrocytic activation, which was correlated to the inhibition of TLR4/NF-κB pathway and the reduction of A1 type neurotoxic astrocyte activation.